Ally Bridge Group

About The Fund

Ally Bridge Group is a cross-border healthcare investment group that commits to various stages of life science companies in China, the United States, and Europe. Founded in 2013 and headquartered in Hong Kong, they focus on biopharmaceuticals, medical devices, and healthcare IT sectors. They manage assets with a presence in New York and Hong Kong and have been involved in over $6 billion of transactions since inception. Their mission is to generate superior risk-adjusted returns for investors while addressing unmet medical needs, by combining scientific and clinical research with M&A and capital markets expertise. They bridge the gap between private and public markets, investing in the global healthcare industry across the capital structure in two complementary strategies: private equity, established initially in 2013, and public equity, a long-biased strategy launched in 2018. They pursue superior returns through a deep understanding of value across both markets and aim to leverage synergies across their platforms to secure opportunities in high-impact life science innovation. The team comprises seasoned professionals with diverse backgrounds from companies like CRG, Intercept Pharmaceuticals, Jefferies, Goldman Sachs, and more. Investments are made across a variety of healthcare subsectors and stages, focusing on companies that potentially transform healthcare. Examples include but are not limited to Aerin Medical, Arbor Biotechnologies, Ceribell, CMR Surgical, Elligo Health Research, Endeavor BioMedicines, Imperative Care, Insightec, Kestra Medical Technologies, LightForce, and Luoxin Pharmaceuticals Group. Ally Bridge Group aims to partner with such companies throughout their entire lifecycle, emphasizing diversified investment in global healthcare innovation.